Athersys Inc ATHXQ
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.00
- Day Range
- $0.00–0.00
- 52-Week Range
- $0.00–1.14
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $271,562.57
- Volume/Avg
- 40,472 / 341,528
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.09
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Athersys Inc is a biotechnology company engaged in the field of regenerative medicine. It consists of research, clinical development, manufacturing, and manufacturing process development activities. The firm's main product is Multistem cell therapy. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 24
- Website
- https://www.athersys.com
Valuation
|
Metric
|
ATHXQ
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 1.09 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ATHXQ
|
|---|---|
Quick Ratio | 0.03 |
Current Ratio | 0.06 |
Interest Coverage | — |
Quick Ratio
ATHXQ
Profitability
|
Metric
|
ATHXQ
|
|---|---|
Return on Assets (Normalized) | −121.73% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ATHXQ
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Lxtpwwjlp | Vmtp | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jphxzzssl | Tgpkjg | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Jbkycbq | Vntkx | $97.8 Bil | |
MRNA
| Moderna Inc | Fdsxqjbq | Vlzg | $41.3 Bil | |
ARGX
| argenx SE ADR | Klzysqzfj | Rlp | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Rlptzptx | Svkp | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Kybwtdkb | Gzmtxr | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mydxstz | Pnnjpf | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Jkhmmcqlj | Lmqgs | $12.5 Bil | |
INCY
| Incyte Corp | Pxnwwnzq | Tphmr | $11.6 Bil |